Company intelligence / Profile preview
Agora Open Science Trust
- Ownership
- Private
- Development stage
- Other
Overview
Agora Open Science Trust operates as a Canadian charity dedicated to accelerating the development of affordable new medicines through an open science model. It owns two key subsidiaries—M4K Pharma Inc. and M4ND Pharma Inc.—which focus on rare pediatric cancers and neurodegenerative diseases respectively. The lead program targets diffuse intrinsic pontine glioma with a kinase inhibitor currently in late preclinical development; additional programs are at earlier stages. The organization eschews patents in favor of regulatory exclusivity to ensure affordability and reinvests all proceeds into further open-science initiatives.
- Therapeutic areas
- OncologyRare DiseasesNeurology
- Modalities
- Small moleculePotentially others via open science collaborations
- Industry
- Biotech
Drug pipeline
1 assetPartnerships
Beyond the preview
Go deeper on Agora Open Science Trust.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Agora Open Science Trust.